A Randomized, Double-blind, Placebo-controlled, Pharmacokinetic, Safety and Tolerability, and Exploratory Efficacy and Pharmacodynamic Effects Study of RO4917523 in Adult Patients With Fragile X Syndrome.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Pharmacokinetic, Safety and Tolerability, and Exploratory Efficacy and Pharmacodynamic Effects Study of RO4917523 in Adult Patients With Fragile X Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Basimglurant (Primary)
  • Indications Behavioural symptoms; Cognition disorders; Fragile X syndrome
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 23 May 2013 Actual initiation date changed from Sep 2011 to Jan 2011 as reported by ClinicalTrials.gov.
    • 09 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top